Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.
Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.
No product to sell yet and no revenue; it is funded by raising capital, and value rests on a topical rapamycin gel clearing its late-stage trial and FDA review for lymphatic malformations. Rare-disease drugs are sold to a small group of specialists, so launch economics rest on a small patient pool.
Moat: none (IP / patents). Addresses rare skin diseases with no approved treatments, but is clinical-stage with small target populations.
Headquarters: Wayne, Pennsylvania, US · Founded: 2015 · Employees: 29
Size Palvella Therapeutics (PVLA) is a United States Health Care company (Biotechnology) with a market value of $2.14B, the 1730th largest of 3,085 United States companies the cockpit tracks. Shares closed at $146.58 on 18 Nov 2026.
Performance Over six months the shares gained 26.9%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +9.4%).
Short interest Short interest is 17.8% of the free float (30 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $25.9M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | $0 | $0 | $0 | $0 | $23.1M |
| EBITDA | n/a | -$38.6M | -$14.1M | -$11.9M | -$40.7M |
| Net income | -$75.0M | -$41.7M | -$17.4M | $18.7M | -$33.3M |
| Free cash flow | n/a | -$25.0M | -$10.8M | -$13.7M | -$61.0M |
| Capital expenditure | n/a | $0 | $0 | $0 | $1.04M |
| Total debt | n/a | $18.4M | $11.9M | $78.7M | $13.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Palvella Therapeutics PVLA | $2.14B | +27% | -100% | n/a | n/a | n/a |
| Krystal Biotech KRYS | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PVLA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.3% | -4.9% | 2nd highest of 21 |
| 6-month return | +26.9% | -10.8% | 7th highest of 20 |
| Distance from 52-week high | -18.5% | -34.1% | 5th highest of 21 |
| Revenue growth (TTM) | -100.0% | +9.4% | 2nd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |